Study to Assess the Safety and Efficacy of Asacol (1.2 to 4.8 g/Day) Administered as 400 mg Delayed-release Tablets Given Every 12 Hours for 6 Weeks to Children and Adolescents With Mildly-to-Moderately Active Ulcerative Colitis.

Trial Profile

Study to Assess the Safety and Efficacy of Asacol (1.2 to 4.8 g/Day) Administered as 400 mg Delayed-release Tablets Given Every 12 Hours for 6 Weeks to Children and Adolescents With Mildly-to-Moderately Active Ulcerative Colitis.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2014

At a glance

  • Drugs Mesalazine (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Sponsors Procter & Gamble; Warner Chilcott
  • Most Recent Events

    • 22 May 2012 Results presented at Digestive Disease Week 2012.
    • 04 Apr 2012 Actual initiation date changed from Aug 2008 to Dec 2008 as reported by ClinicalTrials.gov.
    • 03 Apr 2012 Actual end date changed from Feb 2011 to Mar 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top